Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning

&NA; Increase in global population and growing disease burden due to the emergence of infectious diseases (Zika virus), multidrug‐resistant pathogens, drug‐resistant cancers (cisplatin‐resistant ovarian cancer) and chronic diseases (arterial hypertension) necessitate effective therapies to improve health outcomes. However, the rapid increase in drug development cost demands innovative and sustainable drug discovery approaches. Drug repositioning, the discovery of new or improved therapies by reevaluation of approved or investigational compounds, solves a significant gap in the public health setting and improves the productivity of drug development. As the number of drug repurposing investigations increases, a new opportunity has emerged to understand factors driving drug repositioning through systematic analyses of drugs, drug targets and associated disease indications. However, such analyses have so far been hampered by the lack of a centralized knowledgebase, benchmarking data sets and reporting standards. To address these knowledge and clinical needs, here, we present RepurposeDB, a collection of repurposed drugs, drug targets and diseases, which was assembled, indexed and annotated from public data. RepurposeDB combines information on 253 drugs [small molecules (74.30%) and protein drugs (25.29%)] and 1125 diseases. Using RepurposeDB data, we identified pharmacological (chemical descriptors, physicochemical features and absorption, distribution, metabolism, excretion and toxicity properties), biological (protein domains, functional process, molecular mechanisms and pathway cross talks) and epidemiological (shared genetic architectures, disease comorbidities and clinical phenotype similarities) factors mediating drug repositioning. Collectively, RepurposeDB is developed as the reference database for drug repositioning investigations. The pharmacological, biological and epidemiological principles of drug repositioning identified from the meta‐analyses could augment therapeutic development.

[1]  Pak Chung Sham,et al.  GWASdb v2: an update database for human genetic variants identified by genome-wide association studies , 2015, Nucleic Acids Res..

[2]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[3]  David A. Lee,et al.  Functional classification of CATH superfamilies: a domain-based approach for protein function annotation , 2015, Bioinform..

[4]  R. M. Owen,et al.  An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.

[5]  Christoph Steinbeck,et al.  BiNChE: A web tool and library for chemical enrichment analysis based on the ChEBI ontology , 2015, BMC Bioinformatics.

[6]  Li Li,et al.  An Integrative Pipeline for Multi-Modal Discovery of Disease Relationships , 2014, Pacific Symposium on Biocomputing.

[7]  A. Barabasi,et al.  Uncovering disease-disease relationships through the incomplete interactome , 2015, Science.

[8]  Xiang Zhang,et al.  Drug repositioning by integrating target information through a heterogeneous network model , 2014, Bioinform..

[9]  P. Karp,et al.  Computational prediction of human metabolic pathways from the complete human genome , 2004, Genome Biology.

[10]  D J Rogers,et al.  A Computer Program for Classifying Plants. , 1960, Science.

[11]  David S. Wishart,et al.  MSEA: a web-based tool to identify biologically meaningful patterns in quantitative metabolomic data , 2010, Nucleic Acids Res..

[12]  Christopher G Chute,et al.  Invited commentary: Observational research in the age of the electronic health record. , 2014, American journal of epidemiology.

[13]  K. Pearce,et al.  The Nuclear Receptor Superfamily and Drug Discovery , 2006, ChemMedChem.

[14]  A. Butte,et al.  A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. , 2013, Cancer discovery.

[15]  Niedelman Ml.  Uses and abuses of drugs, new and old, in dermatology. , 1954 .

[16]  Gary H Lyman,et al.  Biomarker Tests for Molecularly Targeted Therapies--The Key to Unlocking Precision Medicine. , 2016, The New England journal of medicine.

[17]  M. Campillos,et al.  Molecularly and clinically related drugs and diseases are enriched in phenotypically similar drug-disease pairs , 2014, Genome Medicine.

[18]  M. Maggiolini,et al.  G protein-coupled receptors: novel targets for drug discovery in cancer , 2010, Nature Reviews Drug Discovery.

[19]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[20]  Kimberly Van Auken,et al.  Recent advances in biocuration: Meeting Report from the fifth International Biocuration Conference , 2012, Database J. Biol. Databases Curation.

[21]  Taha A. Kass-Hout,et al.  Digital Drug Safety Surveillance: Monitoring Pharmaceutical Products in Twitter , 2014, Drug Safety.

[22]  Yen S. Low,et al.  Text Mining for Adverse Drug Events: the Promise, Challenges, and State of the Art , 2014, Drug Safety.

[23]  François Schiettecatte,et al.  OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders , 2014, Nucleic Acids Res..

[24]  Tony Sawford,et al.  Understanding how and why the Gene Ontology and its annotations evolve: the GO within UniProt , 2014, GigaScience.

[25]  M. Llinás,et al.  Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  Eve A Kerr,et al.  The impact of comorbid chronic conditions on diabetes care. , 2006, Diabetes care.

[27]  Joel Dudley,et al.  Network-Based Elucidation of Human Disease Similarities Reveals Common Functional Modules Enriched for Pluripotent Drug Targets , 2010, PLoS Comput. Biol..

[28]  Mulin Jun Li,et al.  Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .

[29]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[30]  Khader Shameer,et al.  Computational and experimental advances in drug repositioning for accelerated therapeutic stratification. , 2015, Current topics in medicinal chemistry.

[31]  Philip E. Bourne,et al.  PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..

[32]  Joel Dudley,et al.  Exploiting drug-disease relationships for computational drug repositioning , 2011, Briefings Bioinform..

[33]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[34]  K. Dolinski,et al.  Use and misuse of the gene ontology annotations , 2008, Nature Reviews Genetics.

[35]  Maria F. Sassano,et al.  Automated design of ligands to polypharmacological profiles , 2012, Nature.

[36]  Ning Ma,et al.  BLAST+: architecture and applications , 2009, BMC Bioinformatics.

[37]  Khader Shameer,et al.  In silico methods for drug repurposing and pharmacology , 2016, Wiley interdisciplinary reviews. Systems biology and medicine.

[38]  Davide Heller,et al.  STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..

[39]  J. Medina-Franco,et al.  Toward Drug Repurposing in Epigenetics: Olsalazine as a Hypomethylating Compound Active in a Cellular Context , 2014, ChemMedChem.

[40]  K. Bretonnel Cohen,et al.  Mining the pharmacogenomics literature - a survey of the state of the art , 2012, Briefings Bioinform..

[41]  M. Khoury,et al.  A navigator for human genome epidemiology , 2008, Nature Genetics.

[42]  A Simon Pickard,et al.  Retracted Publications in the Drug Literature , 2012, Pharmacotherapy.

[43]  Steven E. Brenner,et al.  SCOPe: Structural Classification of Proteins—extended, integrating SCOP and ASTRAL data and classification of new structures , 2013, Nucleic Acids Res..

[44]  Peggy Hall,et al.  The NHGRI GWAS Catalog, a curated resource of SNP-trait associations , 2013, Nucleic Acids Res..

[45]  Joel T Dudley,et al.  Integrative network modeling approaches to personalized cancer medicine. , 2015, Personalized Medicine.

[46]  Kui Xu,et al.  Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases , 2011, Briefings Bioinform..

[47]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[48]  Vincent J. Henry,et al.  OMICtools: an informative directory for multi-omic data analysis , 2014, Database J. Biol. Databases Curation.

[49]  H. van de Waterbeemd,et al.  ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.

[50]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[51]  Egon L. Willighagen,et al.  The Blue Obelisk—Interoperability in Chemical Informatics , 2006, J. Chem. Inf. Model..

[52]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[53]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[54]  M. Hann,et al.  Finding the sweet spot: the role of nature and nurture in medicinal chemistry , 2012, Nature Reviews Drug Discovery.

[55]  J. M. Suh,et al.  PPARγ signaling and metabolism: the good, the bad and the future , 2013, Nature Medicine.

[56]  K M Merz,et al.  GB/SA water model for the Merck molecular force field (MMFF). , 2000, Journal of molecular graphics & modelling.

[57]  Andy D Blackwell.  Measuring cognitive effects: cognition in drug development and repositioning. , 2015, Drug discovery today.

[58]  D. Edwards.  The Role of Coactivators and Corepressors in the Biology and Mechanism of Action of Steroid Hormone Receptors , 2000, Journal of Mammary Gland Biology and Neoplasia.

[59]  Chris T. A. Evelo,et al.  WikiPathways: building research communities on biological pathways , 2011, Nucleic Acids Res..

[60]  Khader Shameer,et al.  Functional repertoire, molecular pathways and diseases associated with 3D domain swapping in the human proteome , 2012, Journal of Clinical Bioinformatics.

[61]  David S. Wishart,et al.  SMPDB 2.0: Big Improvements to the Small Molecule Pathway Database , 2013, Nucleic Acids Res..

[62]  J. Naish,et al.  Diseases associated with ulcerative colitis and Crohn's disease. , 1968, Gut.

[63]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[64]  Joel Dudley,et al.  Translational Bioinformatics Approaches to Drug Development. , 2013, Advances in wound care.

[65]  T L Blundell,et al.  The recognition of protein structure and function from sequence: adding value to genome data. , 1994, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[66]  Avi Ma'ayan,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[67]  B. J. McCabe.  Prevention of food-drug interactions with special emphasis on older adults , 2004, Current opinion in clinical nutrition and metabolic care.

[68]  L. Cardon,et al.  Use of genome-wide association studies for drug repositioning , 2012, Nature Biotechnology.

[69]  María Martín,et al.  UniProt: A hub for protein information , 2015 .

[70]  Food–drug interactions could lower required dose of anticancer drug , 2007, Expert review of pharmacoeconomics & outcomes research.

[71]  George Hripcsak,et al.  Similarity-based modeling in large-scale prediction of drug-drug interactions , 2014, Nature Protocols.

[72]  Xin Chen,et al.  Performance of Similarity Measures in 2D Fragment-Based Similarity Searching: Comparison of Structural Descriptors and Similarity Coefficients , 2002, J. Chem. Inf. Comput. Sci..

[73]  Yanli Wang,et al.  Pathway Analysis for Drug Repositioning Based on Public Database Mining , 2014, J. Chem. Inf. Model..

[74]  Lei Xie,et al.  Harnessing Big Data for Systems Pharmacology , 2016, bioRxiv.

[75]  The Uniprot Consortium,et al.  UniProt: a hub for protein information , 2014, Nucleic Acids Res..

[76]  E. Birney,et al.  Pfam: the protein families database , 2013, Nucleic Acids Res..

[77]  Geoffrey S Ginsburg,et al.  Genomics-enabled drug repositioning and repurposing: insights from an IOM Roundtable activity. , 2014, JAMA.

[78]  C. Lang,et al.  Non-cardiac comorbidities in chronic heart failure , 2006, Heart.

[79]  Tao Jiang,et al.  A maximum common substructure-based algorithm for searching and predicting drug-like compounds , 2008, ISMB.

[80]  Henning Hermjakob,et al.  The Reactome pathway Knowledgebase , 2015, Nucleic acids research.

[81]  Matthew R. Nelson,et al.  The genetics of drug efficacy: opportunities and challenges , 2016, Nature Reviews Genetics.

[82]  Madhusudan Natarajan,et al.  A global analysis of cross-talk in a mammalian cellular signalling network , 2006, Nature Cell Biology.

[83]  David A. Lee,et al.  Functional classification of CATH superfamilies: a domain-based approach for protein function annotation , 2015, Bioinform..

[84]  A. Laupacis,et al.  Drug-drug interactions among elderly patients hospitalized for drug toxicity. , 2003, JAMA.

[85]  J. Bajorath,et al.  Monitoring drug promiscuity over time. , 2014, F1000Research.

[86]  Albert-László Barabási,et al.  A Dynamic Network Approach for the Study of Human Phenotypes , 2009, PLoS Comput. Biol..

[87]  Atul J. Butte,et al.  Ten Years of Pathway Analysis: Current Approaches and Outstanding Challenges , 2012, PLoS Comput. Biol..

[88]  François Schiettecatte,et al.  OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders , 2014, Nucleic Acids Res..

[89]  Qiu Ying Lau,et al.  An FDA-Drug Library Screen for Compounds with Bioactivities against Meticillin-Resistant Staphylococcus aureus (MRSA) , 2015, Antibiotics.

[90]  A. Butte,et al.  Disease Risk Factors Identified Through Shared Genetic Architecture and Electronic Medical Records , 2014, Science Translational Medicine.

[91]  Li Li,et al.  Comparative analyses of population-scale phenomic data in electronic medical records reveal race-specific disease networks , 2016, Bioinform..

[92]  Y Z Chen,et al.  Predicting targeted polypharmacology for drug repositioning and multi- target drug discovery. , 2013, Current medicinal chemistry.

[93]  David Sánchez,et al.  A framework for unifying ontology-based semantic similarity measures: A study in the biomedical domain , 2014, J. Biomed. Informatics.

[94]  Gapped BLAST and PSI-BLAST: A new , 1997 .

[95]  Gary D. Bader,et al.  GeneMANIA Cytoscape plugin: fast gene function predictions on the desktop , 2010, Bioinform..

[96]  A. Kesselheim,et al.  Strategies for Postmarketing Surveillance of Drugs for Rare Diseases , 2014, Clinical pharmacology and therapeutics.

[97]  Pak Chung Sham,et al.  GWASdb: a database for human genetic variants identified by genome-wide association studies , 2011, Nucleic Acids Res..

[98]  Peter Ertl,et al.  Compound Set Enrichment: A Novel Approach to Analysis of Primary HTS Data , 2010, J. Chem. Inf. Model..

[99]  P. Khatri,et al.  A systems biology approach for pathway level analysis. , 2007, Genome research.

[100]  Ruili Huang,et al.  Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen , 2016, Nature Medicine.

[101]  Winston A Hide,et al.  Big data: The future of biocuration , 2008, Nature.

[102]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[103]  M. L. Niedelman.  Uses and abuses of drugs, new and old, in dermatology. , 1954, Pennsylvania medical journal.

[104]  Kenneth H. Buetow,et al.  PID: the Pathway Interaction Database , 2008, Nucleic Acids Res..

[105]  Trey Ideker,et al.  Cytoscape tools for the web age: D3.js and Cytoscape.js exporters , 2014, F1000Research.

[106]  A. Robbins,et al.  What's the relative risk? A method to directly estimate risk ratios in cohort studies of common outcomes. , 2002, Annals of epidemiology.

[107]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[108]  Tao Jiang,et al.  ChemmineR: a compound mining framework for R , 2008, Bioinform..

[109]  Judy H. Cho,et al.  Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease , 2008, Nature Genetics.

[110]  Michael J. Keiser,et al.  Systems pharmacology augments drug safety surveillance , 2014, Clinical pharmacology and therapeutics.

[111]  Zhiyong Lu,et al.  Community challenges in biomedical text mining over 10 years: success, failure and the future , 2016, Briefings Bioinform..

[112]  Alexander A. Morgan,et al.  Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.

[113]  Igor V. Tetko,et al.  Virtual Computational Chemistry Laboratory – Design and Description , 2005, J. Comput. Aided Mol. Des..

[114]  E. Jacoby,et al.  Chemogenomics: an emerging strategy for rapid target and drug discovery , 2004, Nature Reviews Genetics.

[115]  Ralf Herwig,et al.  The ConsensusPathDB interaction database: 2013 update , 2012, Nucleic Acids Res..

[116]  Pankaj Agarwal,et al.  A global pathway crosstalk network , 2008, Bioinform..

[117]  William Loging,et al.  High-throughput electronic biology: mining information for drug discovery , 2007, Nature Reviews Drug Discovery.

[118]  R A Knight,et al.  DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information , 2014, Cell Death and Disease.

[119]  Simon M Lin,et al.  Opportunities for drug repositioning from phenome-wide association studies , 2015, Nature Biotechnology.

[120]  Aaron S Kesselheim,et al.  The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs. , 2015, Health affairs.

[121]  Susana Murteira,et al.  Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature , 2013, Journal of market access & health policy.

[122]  Li Li,et al.  Systematic Identification of Risk Factors for Alzheimer's Disease Through Shared Genetic Architecture and Electronic Medical Records , 2012, Pacific Symposium on Biocomputing.

[123]  Egon L. Willighagen,et al.  The Chemistry Development Kit (CDK): An Open-Source Java Library for Chemo-and Bioinformatics , 2003, J. Chem. Inf. Comput. Sci..

[124]  Vincent Laudet,et al.  Principles for modulation of the nuclear receptor superfamily , 2004, Nature Reviews Drug Discovery.

[125]  E. Steyerberg,et al.  The changing prevalence of comorbidity across the age spectrum. , 2008, Critical reviews in oncology/hematology.

[126]  Jun'ichi Tsujii,et al.  New challenges for text mining: mapping between text and manually curated pathways , 2008, BMC Bioinformatics.

[127]  Christoph Steinbeck,et al.  The ChEBI reference database and ontology for biologically relevant chemistry: enhancements for 2013 , 2012, Nucleic Acids Res..

[128]  Gary D. Bader,et al.  The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function , 2010, Nucleic Acids Res..

[129]  R. Altman,et al.  Data-Driven Prediction of Drug Effects and Interactions , 2012, Science Translational Medicine.

[130]  Henning Hermjakob,et al.  The Reactome pathway knowledgebase , 2013, Nucleic Acids Res..

[131]  Sylvie Ranwez,et al.  The semantic measures library and toolkit: fast computation of semantic similarity and relatedness using biomedical ontologies , 2014, Bioinform..

[132]  J. Loscalzo,et al.  The Emerging Paradigm of Network Medicine in the Study of Human Disease , 2012, Circulation research.

[133]  Mariana L. Neves,et al.  A survey on annotation tools for the biomedical literature , 2014, Briefings Bioinform..

[134]  Ara Darzi,et al.  Preparing for precision medicine. , 2012, The New England journal of medicine.

[135]  Ákos Tarcsay,et al.  Contributions of molecular properties to drug promiscuity. , 2013, Journal of medicinal chemistry.

[136]  Zi Ye,et al.  Survival in patients with poorly compressible leg arteries. , 2012, Journal of the American College of Cardiology.

[137]  Zongliang Yue,et al.  DMAP: a connectivity map database to enable identification of novel drug repositioning candidates , 2015, BMC Bioinformatics.

[138]  Upendra Nagaich,et al.  Drug recall: An incubus for pharmaceutical companies and most serious drug recall of history , 2015, International journal of pharmaceutical investigation.

[139]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[140]  Chris Morley,et al.  Pybel: a Python wrapper for the OpenBabel cheminformatics toolkit , 2008, Chemistry Central journal.

[141]  François G Schellevis,et al.  Comorbidity and guidelines: conflicting interests , 2006, The Lancet.

[142]  N. Bayley,et al.  Failure , 1890, The Hospital.

[143]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[144]  Yanli Wang,et al.  PubChem BioAssay: 2014 update , 2013, Nucleic Acids Res..

[145]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[146]  E. Koonin,et al.  Evolution of protein domain promiscuity in eukaryotes. , 2008, Genome research.

[147]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[148]  Christopher B Forrest,et al.  Comorbidity: Implications for the Importance of Primary Care in ‘Case’ Management , 2003, The Annals of Family Medicine.

[149]  J. Satsangi,et al.  Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. , 2003, Pharmacological research.

[150]  Michael J. Keiser,et al.  The Chemical Basis of Pharmacology , 2010, Biochemistry.

[151]  D. Aoki,et al.  Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning. , 2016, Oncology letters.